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34 Oral Presentations17). 72% of patients had at least 1 medication omitted from their
list at their first pharmacist visit. 367 pharmaceutical care recom-
mendations were made on 76 patients, with 72% of recommenda-
tions accepted. The most frequent recommendations included
osteoporosis prevention/management (n 5 51), calcineurin inhib-
itor dose adjustment (n 5 43), pneumocystis prophylaxis (n5 26),
electrolyte replacement (n 5 25), and antiviral prophylaxis/treat-
ment (n 5 20). 220 medications were identified as requiring
a new written prescription.
Conclusion: Pharmacist involvement in the allogeneic stem cell
transplant clinic has improved medication list accuracy and pharma-
ceutical care of patients.Improvement in Medication List Accuracy
Medication
List
Visit 1
N573
Visit 2
N573 p value
Visit 2
N553
Visit 3
N553 p value
Medication
Omissions
(Mean)
11.1% 5% \0.0001 4.8% 2.6% 0.04
Prescription
Medication
Omissions
(Mean)
5.7% 2.8% 0.001 2.8% 1.4% 0.101
Dose Omission/
Errors (Mean)
8.6% 4.1% \0.0001 4.5% 1.9% 0.006
Schedule Omission/
Errors (Mean)
4.3% 1.1% \0.0001 1.1% 1.1% 0.988
Route Omission/
Errors (Mean)
15.4% 3.1% \0.0001 3.9% 1.8% 0.08
Patients with
Error-Free
Medication List
2.7% 31.5% \0.0001 28.3% 43.4% 0.08
*Visit 2 percentages are slightly different as there are fewer patients with
at least 3 visits.84
MEDACTIONPLAN.COM AS A TOOL FOR PATIENT EDUCATION AND MED-
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Pineiro, L.A.1,2, Vance, E.A.1,2, Fay, J.W.1,2 1Baylor University Medical
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Baylor University Medical Center performs approximately 200
Blood and Marrow transplants annually in the inpatient and out-
patient settings. The medication regimens prescribed for these
patients at discharge are complex, confusing, and often prove
overwhelming to patients during the transplant process. In our
program, pharmacy staff works in conjunction with the physi-
cians to provide medication education and teaching to transplant
patients. We began using MedActionPlan.com, a free web-based
tool that allows for the creation of personalized treatment plans
for patients and saves their records in a program specific data-
base. Each plan includes images of the medications prescribed,
instructions of use, abbreviated drug information for each med-
ication as well as a medication schedule checklist for patient use.
This checklist may be used to record adherence, upcoming ap-
pointments or other relevant medical information. Plans may
be customized to fit individual patient needs and have the option
to be translated into Spanish. All medication plans are accessible
from any computer by a user specific log-on and password.
MedActionPlan.com is secure, and meets all HIPPA require-
ments and Joint Commission’s goals for improving patient safety
and education for medication therapy. The web-based program
also contains an export function, allowing schedules to be sent
directly to patients for their medication managment. These
schedules can be customized into regular-print, large-font or
wallet-sized versions depending on patient-specific needs. In ad-
dition to enhancing communication between the inpatient andoutpatient facilities, MedActionPlan.com has empowered our pa-
tients and their caregivers to be proactive participants in their
healthcareprogram.Patients are able toquickly refer to a centralized
and comprehensivemedication profilewhich allows for significantly
improved understanding of, and ultimately, compliance with com-
plex medication regimens. MedActionPlan.com has proved to be
a valuable resource and has both enhanced the quality of patient ed-
ucation in our transplant program and improved the continuity of
care between inpatient and outpatient settings.85
DEVELOPMENT AND COMPARISON OF LIMITED SAMPLING STRATEGIES
FOR PHARMACOKINETICALLY-GUIDED HIGH-DOSE, INTRAVENOUS BU-
SULFAN
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High-dose, intravenous (IV) busulfan (Bu) is widely used in
stem cell transplantation conditioning regimens, and is favored
for its pharmacokinetic (PK) predictability and complete dose
assurance. A one-compartment, first-order elimination PK
model adequately describes the behavior of Bu following IV ad-
ministration, allowing for prospective targeting of a specific sys-
temic exposure (AUC) to preparative regimens for each
individual patient. Traditional ‘full’ sampling commonly utilizes
9 to11 samples over 10–16 hours, following a 2–3 hr drug infu-
sion , to calculate Bu plasma clearance (ClT). We hypothesized
that 4–5 samples drawn at selected times during the elimination
phase would be sufficiently accurate to calculate ClT. Here we
present a limited sampling strategy (LSS) as basis for the valida-
tion of a Bayesian method that optimizes such sample schema.
Decreasing the number of timepoints would reduce the analyt-
ical, logistical efforts while cost containing. We analyzed Bu PK
in 87 patients to develop a LSS method. From 42 patients, we
collected and analyzed the full sampling data from the 3rd of 4
daily doses and compared the AUC obtained , to that obtained
when using a 5-point LSS. For a 5-point LSS (5 min before
EOI, 4, 6, 10, and 12 hour), the mean daily AUC calculation
was 0.2% lower (5132 vs. 5142 mM-min) with like coefficient
of variation (CV, 18.8% each), compared to the full method.
In a follow-up study, using an additional 11 consecutive pa-
tients, we investigated whether a 4-point LSS (deleting the 5
min prior to the EOI timepoint) was significantly different in
determination of AUC; the 4-point LSS yielded average AUC
that was 3.2% . the 5 point method (985 vs. 954 mM-min)
with variability that was slightly . the 5-point method (CV,
9.6% vs. 13.6%). To determine whether a 4- or 5-point LSS
would be preferable, data on the 1st dose in an additional 45 pa-
tients from an alternative arm of this study were analyzed. The
AUC based on full sampling was then compared with the AUC
from both 5- and 4-point LSS, resulting in AUC differences of
0.3% and 0.6% (6129 vs. 6108 and 6090 mM-min) with nearly
identical variability. The calculated AUC and other PK param-
eters from the 4- and 5-point LSS did not vary significantly
from full method, but greater variability was observed with
the 4-point method. We conclude that prospective validation
of a LSS is warranted and ongoing; demonstrating that 5-sample
LSS is favored for clinical therapeutic dose guidance.86
FAMCICLOVIR PROPHYLAXIS OF VARICELLA ZOSTER VIRUS REACTIVA-
TION IN CHILDREN AFTER HEMATOPOEITIC STEM CELL TRANSPLANTA-
TION
Charbonneau-Allard, A.-M., Therrien, R. UHC Ste-Justine, Montreal,
QC, Canada
Background: The usual varicella zoster virus (VZV) reactiva-
tion prophylaxis used in adults after hematopoietic stem cell
transplantation (HSCT) is oral acyclovir. In our institution, fam-
ciclovir was chosen over acyclovir because of fewer daily doses
Oral Presentations 35and the absence of renal toxicity. Since June 2006, famciclovir is
given after HSCT to children older than 2 years old with a posi-
tive VZV serology and after autologous HSCT for patient at
high risk notably patients with Hodgkin’s lymphoma. However,
famciclovir has no official indication in children, no pediatric
dose is known and there is no reports of famciclovir use in this
indication. After 2 years of use, we evaluated the efficacy and
safety of famciclovir for VZV prophylaxis in children after
HSCT.
Patients and methods : Thirty-three patients, aged 4 to 20
years old, were included in this retrospective study. The inclu-
sion criteria were: HSCT patients, VZV positive serology before
HSCT, prophylactic famciclovir for at least 2 consecutive
months after HSCT. The exclusion criteria were: acyclovir or va-
lacyclovir prophylaxis, acyclovir, valacyclovir or famciclovir in
treatment before famciclovir prophylaxis.
Results : As of now, only 48% of our patients have com-
pleted their prophylaxis. We evaluated the famciclovir prophy-laxis for a period of 2 to 23 months during the prophylaxis and
up to 14 months after the prophylaxis was stopped. The daily
average dose was 18.2 6 4.3 mg/kg and 561 6 107 mg/m2.
The dose was mainly prescribed by age; children aged \12
years old received 250 mg twice daily and children aged $12
years old received 500 mg twice daily. The average time be-
tween HSCT and the beginning of the prophylaxis was 33
days for allogenic HSCT and13 days for autologous HSCT.
The average length of a completed prophylaxis was 233 6
83 (134 – 400) days. Only one patient was diagnosed with
shingles during the prophylaxis but he was not compliant to
his medication. Four patients developped shingles after the
prophylaxis was stopped. There was no discontinuation due
to side effects.
Conclusion : Famciclovir, at a dose of 18.2 mg/kg/day divided in
two doses in children aged 4 to 20 years old, seem to be as effective
as several different acyclovir regimens in adults for preventing VZV
disease after HSCT.
